A decade of clinical development of PARP inhibitors in perspective
Open accessThe DOI matches its Crossref record; 98 of the 100 references it cites were found in a registry or an index.
Abstract
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be exploited therapeutically. In 2009, a first-in-man clinical trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/BRCA2 deficiency. In this review, we summarize a decade of PARP inhibitor clinical development, a work that has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). Over the past 10 years, our knowledge on the mechanism of action of PARP inhibitor as well as how tumours become resistant has been extended, and we summarise this work here. We also discuss opportunities for expanding the precision medicine approach with PARP inhibitors, identifying a wider population who could benefit from this drug class. This includes developing and validating better predictive biomarkers for patient stratification, mainly based on homologous recombination defects beyond BRCA1/BRCA2 mutations, identifying DNA repair deficient tumours in other cancer types such as prostate or pancreatic cancer, or by designing combination therapies with PARP inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“PARP inhibitors are used as tumor therapy drugs, specifically targeting cancer cells with genetic defects in DNA repair genes such as BRCA1, exploiting their synthetic lethal relationship with PARP1 (Mateo et al, 2019).”
From Network integration of thermal proteome profiling with multi-omics data decodes PARP inhibition (2024) · cites this paper as Mateo et al, 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 1×
“Genomic signatures or scars represent repetitive patterns of DNA alterations that translate an underlying biological condition [56].”
BackgroundSelf-citationIntegrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683 · cited 2×
“In 2005, two seminal studies demonstrated that tumour cells lacking BRCA1 or BRCA2, key tumour suppressor proteins involved in double-strand DNA break (DSB) repair by homologous recombination (HR), are selectively sensitive to small molecule inhibitors of the PARP family of DNA repair enzymes [1, 2].”
BackgroundSelf-citationSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634 · cited 1×
“A first-in-human clinical trial of KU-0059436 (KuDOS Pharmaceuticals/ AstraZeneca, later named AZD-2281/olaparib) was conducted to establish a recommended dose and to generate preliminary data in a biomarker-defined population [6, 7].”
MethodSelf-citationZehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380 · cited 1×
“As interest has evolved beyond gBRCA1/2 mutations, multiplexed NGS assays of both germline and somatic DNA have become the preferred tool for patient identification [53, 54].”
BackgroundOlaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · cited 1×
“In 2017, results from a randomized phase III trial (OlympiAD) in HER2-negative, gBRCA1/2 mutation-associated, metastatic breast cancer comparing olaparib with physician’s treatment choice (capecitabine, eribulin, vinorelbine, or gemcitabine) were reported [36].”
BackgroundMaintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Moore, K., Colombo, N., Scambia, G., Kim, B.-G., Oaknin, A., Friedlander, M., Lisyanskaya, A., Floquet, A., Leary, A., Sonke, G. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810858 · Cited by 2,870 · cited 1×
“30) in the maintenance setting after first-line platinum-based chemotherapy in FIGO stage III/IV high-grade ovarian cancer [25].”
BackgroundSelf-citationA rapid method for determining sequences in DNA by primed synthesis with DNA polymerase
Sanger, F., & Coulson, A. R. (1975) · Journal of Molecular Biology · doi:10.1016/0022-2836(75)90213-2 · Cited by 2,709 · cited 1×
“During early phases of PARPi development, most efforts centred on detecting gBRCA1/ 2 mutations, initially using Sanger sequencing [52].”
MethodNiraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451 · cited 1×
“The phase III NOVA trial randomized 555 patients with platinum-sensitive recurrent HGOC to maintenance niraparib or placebo treatment after second or later line of platinumbased chemotherapy [28].”
BackgroundAudeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Self-citationTrapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192 · cited 1×
“Although the precise mechanisms that explain PARP1 trapping are still unclear, two have been proposed: (i) PARPi either prevents the release of PARP1 from DNA by inhibiting autoPARylation [11] or (ii) PARPi binding to the catalytic site causes allosteric changes in the PARP1 structure enhancing DNA avidity [3, 10, 12].”
BackgroundDNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., Nava Rodrigues, D., Robinson, D., Omlin, A., Tunariu, N., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506859 · Cited by 2,185 · cited 1×
“Retrospective genomic assessment of trial biopsies identified a strong association between antitumour activity and alterations in different DNA repair genes [46].”
BackgroundSelf-citationTalazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175 · cited 1×
“This approach was validated in another phase III trial with talazoparib administered continuously compared with the same chemotherapy regimens [37], with a median PFS of 8.”
MethodOlaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855 · cited 1×
“5 m for olaparib and placebo, respectively) [24].”
BackgroundColeman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693 · cited 1×
“The ARIEL3 phase III trial evaluated rucaparib as maintenance treatment following platinum-based therapy in recurrent high-grade ovarian cancer, randomizing 564 women to rucaparib versus placebo (2 : 1) [31].”
MethodSelf-citationInherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer
Pritchard, C. C., Mateo, J., Walsh, M. F., De Sarkar, N., Abida, W., Beltran, H., Garofalo, A., Gulati, R., Carreira, S., Eeles, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603144 · Cited by 1,680 · cited 1×
“Several genomic landscape studies have estimated that 8%–12% of all mPrC have BRCA2 mutations and homozygous deletions, with around half of these cases being linked to a germline mutation [43, 44].”
BackgroundSelf-citationOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671 · cited 1×
“A basket trial of olaparib in patients with gBRCA1/2 mutations identified responding patients beyond the ovarian or breast cancer population, suggesting that other HR-defective tumours could be suitable for PARPi treatment [41].”
BackgroundTutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
Self-citationLedermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
Self-citationSwisher, E. M., Lin, K. K., Oza, A. M., Scott, C. L., Giordano, H., Sun, J., Konecny, G. E., Coleman, R. L., Tinker, A. V., O'Malley, D. M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30559-9 · Cited by 1,196
Self-citationGelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117 · cited 1×
“Confirmed RECIST responses with olaparib were seen in 41% and 24% of gBRCA mutation carriers and non-carriers, respectively [18], suggesting there could be a target population beyond gBRCA mutation carriers.”
BackgroundHRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Davies, H., Glodzik, D., Morganella, S., Yates, L. R., Staaf, J., Zou, X., Ramakrishna, M., Martin, S., Boyault, S., Sieuwerts, A. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4292 · Cited by 1,086 · cited 2×
“These tumours accumulate small insertions-deletions and loss-of-heterozygosity events [57].”
BackgroundSelf-citationFong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010 · cited 1×
“There is a clear association between the platinum-sensitivity, defined based on the time gap from last platinum exposure to disease progression, and response to PARPi [20].”
BackgroundSelf-citationPARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression
Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981
Rottenberg, S., Jaspers, J. E., Kersbergen, A., van der Burg, E., Nygren, A. O. H., Zander, S. A. L., Derksen, P. W. B., de Bruin, M., Zevenhoven, J., Lau, A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806092105 · Cited by 956 · cited 1×
“Beyond mechanisms rewiring the DNA damage response, increased expression of ATP-binding cassette transporters, such as the P-glycoprotein efflux pump have been shown to reduce the efficacy of PARPi [84].”
BackgroundHomologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0714 · Cited by 945 · cited 1×
“Numerous mechanisms of acquired resistance to PARPi have been described in pre-clinical and clinical studies [65, 66]; these can be grouped into three main classes (Figure 2).”
BackgroundSchlacher, K., Wu, H., & Jasin, M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.015 · Cited by 936
Replication fork stability confers chemoresistance in BRCA-deficient cells
Ray Chaudhuri, A., Callen, E., Ding, X., Gogola, E., Duarte, A. A., Lee, J.-E., Wong, N., Lafarga, V., Calvo, J. A., Panzarino, N. J., et al. (2016) · Nature · doi:10.1038/nature18325 · Cited by 930 · cited 1×
“For example, BRCA2-mutant cells with loss of the MLL3/4 complex protein, were reported to become PARPi-resistant by fork protection through reduction of MRE11 recruitment to stalled forks [80].”
BackgroundThe long tail of oncogenic drivers in prostate cancer
PCF/SU2C International Prostate Cancer Dream Team, Armenia, J., Wankowicz, S. A. M., Liu, D., Gao, J., Kundra, R., Reznik, E., Chatila, W. K., Chakravarty, D., Han, G. C., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0078-z · Cited by 867 · cited 1×
“), up to 20%–25% of all mPrC harbour gene defects in different DDR pathways, which represents a significant enrichment when compared with localized, often indolent, prostate tumours [45].”
BackgroundLoibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768 · cited 1×
“Conversely, veliparib, which has lower trapping potency, has not demonstrated significantly increased antitumour activity when combined with neoadjuvant platinumbased chemotherapy [40].”
BackgroundStereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J., Takeda, S., Morris, J., Teicher, B., Doroshow, J. H., & Pommier, Y. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 756 · cited 2×
“PARP1 autoPARylation eventually leads to its own release from the site of DNA damage [9, 10].”
BackgroundGenomic Hallmarks and Structural Variation in Metastatic Prostate Cancer
Quigley, D. A., Dang, H. X., Zhao, S. G., Lloyd, P., Aggarwal, R., Alumkal, J. J., Foye, A., Kothari, V., Perry, M. D., Bailey, A. M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.06.039 · Cited by 733
DNA Damage and Repair Biomarkers of Immunotherapy Response
Mouw, K. W., Goldberg, M. S., Konstantinopoulos, P. A., & D'Andrea, A. D. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0226 · Cited by 645 · cited 1×
“A range of clinical trials exploring these combinations are now underway and may provide evidence of this clinical effect [95].”
BackgroundInactivation of CDK12 Delineates a Distinct Immunogenic Class of Advanced Prostate Cancer
Wu, Y.-M., Cieślik, M., Lonigro, R. J., Vats, P., Reimers, M. A., Cao, X., Ning, Y., Wang, L., Kunju, L. P., de Sarkar, N., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.034 · Cited by 598
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585 · cited 1×
“combinations with ATR or HDAC inhibitors) [86, 87], take advantage of the relation between angiogenesis, hypoxia and DNA damage [88], or exploit the cross-talk between DDR and hormone receptor-driven pathways, such as ER and AR in breast and prostate cancer, respectively [89–91].”
BackgroundNorquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.06.053 · Cited by 571 · cited 1×
“Several genomic landscape studies have estimated that 8%–12% of all mPrC have BRCA2 mutations and homozygous deletions, with around half of these cases being linked to a germline mutation [43, 44].”
BackgroundSelf-citationSandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70240-7 · Cited by 562 · cited 2×
“The original phase I trial of niraparib included a small prostate cancer expansion cohort, with promising signs of clinical benefit [26].”
BackgroundMethodSelf-citationOza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547 · cited 1×
“Combinations with DNA damaging chemotherapy aim to maximize the effect of DNA damage, but they have been proved challenging due to overlapping toxicities [85].”
BackgroundClinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
Kurian, A. W., Hare, E. E., Mills, M. A., Kingham, K. E., McPherson, L., Whittemore, A. S., McGuire, V., Ladabaum, U., Kobayashi, Y., Lincoln, S. E., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.6607 · Cited by 485
Shen, Y., Rehman, F. L., Feng, Y., Boshuizen, J., Bajrami, I., Elliott, R., Wang, B., Lord, C. J., Post, L. E., & Ashworth, A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1391 · Cited by 479 · cited 1×
“rucaparib, olaparib, talazoparib, niraparib) [13].”
Self-citationKaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470 · cited 1×
“7) for the olaparib 200 mg, olaparib 400 mg, and PLD cohorts, respectively [17].”
BackgroundSelf-citationHuman RECQ1 promotes restart of replication forks reversed by DNA topoisomerase I inhibition
Berti, M., Ray Chaudhuri, A., Thangavel, S., Gomathinayagam, S., Kenig, S., Vujanovic, M., Odreman, F., Glatter, T., Graziano, S., Mendoza-Maldonado, R., et al. (2013) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2501 · Cited by 452
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
Lord, C. J., & Ashworth, A. (2013) · Nature Medicine · doi:10.1038/nm.3369 · Cited by 449 · cited 1×
“Numerous mechanisms of acquired resistance to PARPi have been described in pre-clinical and clinical studies [65, 66]; these can be grouped into three main classes (Figure 2).”
BackgroundSelf-citationPettitt, S. J., Krastev, D. B., Brandsma, I., Dréan, A., Song, F., Aleksandrov, R., Harrell, M. I., Menon, M., Brough, R., Campbell, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03917-2 · Cited by 449 · cited 1×
“Mutations in the DNA-binding domains of PARP1 represent other likely relevant mechanisms of resistance, although clinical data are sparse [82].”
BackgroundSelf-citationDual Roles of PARP-1 Promote Cancer Growth and Progression
Schiewer, M. J., Goodwin, J. F., Han, S., Brenner, J. C., Augello, M. A., Dean, J. L., Liu, F., Planck, J. L., Ravindranathan, P., Chinnaiyan, A. M., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0120 · Cited by 442 · cited 1×
“Recently, the role of PARP1 as transcriptional regulator for nuclear factors has raised some interest, due to the role of estrogen/ progesterone and androgen receptors in breast and prostate cancer, respectively [15].”
BackgroundCruz, C., Castroviejo-Bermejo, M., Gutiérrez-Enríquez, S., Llop-Guevara, A., Ibrahim, Y. H., Gris-Oliver, A., Bonache, S., Morancho, B., Bruna, A., Rueda, O. M., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy099 · Cited by 433 · cited 2×
“Expression of functional hypomorphic variants of BRCA1 has been associated with resistance to PARPi in patient-derived models [63, 71, 72].”
BackgroundSelf-citationCirculating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Goodall, J., Mateo, J., Yuan, W., Mossop, H., Porta, N., Miranda, S., Perez-Lopez, R., Dolling, D., Robinson, D. R., Sandhu, S., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0261 · Cited by 421
Self-citationShieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
Dev, H., Chiang, T.-W. W., Lescale, C., de Krijger, I., Martin, A. G., Pilger, D., Coates, J., Sczaniecka-Clift, M., Wei, W., Ostermaier, M., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0140-1 · Cited by 417 · cited 1×
“There is also evidence in preclinical models of the co-existence of other mechanisms of resistance involving, for example, BRCA1 restoration with the removal of barriers to DNA end resection via loss of 53BP1 or proteins from the Shieldin complex, among others [75, 76].”
BackgroundSelf-citationKondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Clarke, N., Wiechno, P., Alekseev, B., Sala, N., Jones, R., Kocak, I., Chiuri, V. E., Jassem, J., Fléchon, A., Redfern, C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30365-6 · Cited by 396 · cited 1×
“Beyond their use as single agents in HR-defective tumours, PARP1 is an interesting target in prostate cancer based on the cross-talk between the androgen receptor (main oncogenic driver of prostate cancer) and DDR pathways; results from phase II combination trials of PARPi- and ARtargeting agents have now been reporte…”
BackgroundYazinski, S. A., Comaills, V., Buisson, R., Genois, M.-M., Nguyen, H. D., Ho, C. K., Todorova Kwan, T., Morris, R., Lauffer, S., Nussenzweig, A., et al. (2017) · Genes & Development · doi:10.1101/gad.290957.116 · Cited by 395 · cited 1×
“Yazinski and colleagues further demonstrated that PARPinhibitor resistant, BRCA1-deficient cells become dependent on ATR for survival [81].”
Backgroundde Bono, J., Ramanathan, R. K., Mina, L., Chugh, R., Glaspy, J., Rafii, S., Kaye, S., Sachdev, J., Heymach, J., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 387 · cited 1×
“In the initial phase I study of talozaparib, two patients with pancreatic cancer and mutations in BRCA2 and PALB2, respectively, achieved radiological partial responses [49].”
BackgroundSelf-citationGogola, E., Duarte, A. A., de Ruiter, J. R., Wiegant, W. W., Schmid, J. A., de Bruijn, R., James, D. I., Guerrero Llobet, S., Vis, D. J., Annunziato, S., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.008 · Cited by 374
Bajrami, I., Frankum, J. R., Konde, A., Miller, R. E., Rehman, F. L., Brough, R., Campbell, J., Sims, D., Rafiq, R., Hooper, S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2541 · Cited by 373
Self-citationA Hormone–DNA Repair Circuit Governs the Response to Genotoxic Insult
Goodwin, J. F., Schiewer, M. J., Dean, J. L., Schrecengost, R. S., de Leeuw, R., Han, S., Ma, T., Den, R. B., Dicker, A. P., Feng, F. Y., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0108 · Cited by 364
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
Barber, L. J., Sandhu, S., Chen, L., Campbell, J., Kozarewa, I., Fenwick, K., Assiotis, I., Rodrigues, D. N., Reis-Filho, J. S., Moreno, V., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4140 · Cited by 336
Self-citationPARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, R. M., Muirhead, G., Krastev, D. B., Adam, J., Morel, D., Garrido, M., Lamb, A., Hénon, C., Dorvault, N., Rouanne, M., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci123319 · Cited by 332
Self-citationGraeser, M., McCarthy, A., Lord, C. J., Savage, K., Hills, M., Salter, J., Orr, N., Parton, M., Smith, I. E., Reis-Filho, J. S., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1027 · Cited by 327 · cited 1×
“Their challenge raises from the need to be tested in samples with DNA damage and proliferating cells, since HR is cell cycle-related [62].”
BackgroundSelf-citationKondrashova, O., Topp, M., Nesic, K., Lieschke, E., Ho, G.-Y., Harrell, M. I., Zapparoli, G. V., Hadley, A., Holian, R., Boehm, E., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05564-z · Cited by 296 · cited 1×
“Similarly, while epigenetic silencing of BRCA1 and RAD51C by hypermethylation of promoter regions results in PARPi sensitivity, demethylation is associated with mRNA re-expression and development of resistance [64, 73, 74].”
BackgroundMurai, J., Zhang, Y., Morris, J., Ji, J., Takeda, S., Doroshow, J. H., & Pommier, Y. (2014) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.210146 · Cited by 293 · cited 1×
“Although the precise mechanisms that explain PARP1 trapping are still unclear, two have been proposed: (i) PARPi either prevents the release of PARP1 from DNA by inhibiting autoPARylation [11] or (ii) PARPi binding to the catalytic site causes allosteric changes in the PARP1 structure enhancing DNA avidity [3, 10, 12].”
BackgroundKim, H., George, E., Ragland, R. L., Rafail, S., Zhang, R., Krepler, C., Morgan, M. A., Herlyn, M., Brown, E. J., & Simpkins, F. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2273 · Cited by 291 · cited 1×
“combinations with ATR or HDAC inhibitors) [86, 87], take advantage of the relation between angiogenesis, hypoxia and DNA damage [88], or exploit the cross-talk between DDR and hormone receptor-driven pathways, such as ER and AR in breast and prostate cancer, respectively [89–91].”
BackgroundEnvisioning the future of early anticancer drug development
Yap, T. A., Sandhu, S. K., Workman, P., & de Bono, J. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2870 · Cited by 281 · cited 1×
“A first-in-human clinical trial of KU-0059436 (KuDOS Pharmaceuticals/ AstraZeneca, later named AZD-2281/olaparib) was conducted to establish a recommended dose and to generate preliminary data in a biomarker-defined population [6, 7].”
MethodOza, A. M., Tinker, A. V., Oaknin, A., Shapira-Frommer, R., McNeish, I. A., Swisher, E. M., Ray-Coquard, I., Bell-McGuinn, K., Coleman, R. L., O'Malley, D. M., et al. (2017) · Gynecologic Oncology · doi:10.1016/j.ygyno.2017.08.022 · Cited by 281 · cited 1×
“In addition, rucaparib is also registered by the FDA and EMA for BRCA1/2mutation associated ovarian cancer who have received at least 2 previous lines of chemotherapy [33].”
BackgroundSelf-citationHopkins, T. A., Shi, Y., Rodriguez, L. E., Solomon, L. R., Donawho, C. K., DiGiammarino, E. L., Panchal, S. C., Wilsbacher, J. L., Gao, W., Olson, A. M., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0191-t · Cited by 270 · cited 1×
“Although the precise mechanisms that explain PARP1 trapping are still unclear, two have been proposed: (i) PARPi either prevents the release of PARP1 from DNA by inhibiting autoPARylation [11] or (ii) PARPi binding to the catalytic site causes allosteric changes in the PARP1 structure enhancing DNA avidity [3, 10, 12].”
BackgroundWang, Y., Bernhardy, A. J., Cruz, C., Krais, J. J., Nacson, J., Nicolas, E., Peri, S., van der Gulden, H., van der Heijden, I., O'Brien, S. W., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0186 · Cited by 269
Self-citationA RAD 51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Castroviejo‐Bermejo, M., Cruz, C., Llop‐Guevara, A., Gutiérrez‐Enríquez, S., Ducy, M., Ibrahim, Y. H., Gris‐Oliver, A., Pellegrino, B., Bruna, A., Guzmán, M., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809172 · Cited by 268 · cited 2×
“Similarly, while epigenetic silencing of BRCA1 and RAD51C by hypermethylation of promoter regions results in PARPi sensitivity, demethylation is associated with mRNA re-expression and development of resistance [64, 73, 74].”
BackgroundSelf-citationStabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein
Lomonosov, M., Anand, S., Sangrithi, M., Davies, R., & Venkitaraman, A. R. (2003) · Genes & Development · doi:10.1101/gad.279003 · Cited by 256
Kristeleit, R., Shapiro, G. I., Burris, H. A., Oza, A. M., LoRusso, P., Patel, M. R., Domchek, S. M., Balmaña, J., Drew, Y., Chen, L.-M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2796 · Cited by 238 · cited 1×
“Lastly, rucaparib (Clovis Oncology) was initially developed for IV administration but later evolved into an orally available drug, with a recommended dose of 600 mg twice daily [29, 30].”
BackgroundFailure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212 · cited 1×
“After an unsuccessful phase III study in triple-negative breast cancer, preclinical work demonstrated that iniparib was not a bona fide PARPi [14].”
Backgroundter Brugge, P., Kristel, P., van der Burg, E., Boon, U., de Maaker, M., Lips, E., Mulder, L., de Ruiter, J., Moutinho, C., Gevensleben, H., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw148 · Cited by 211 · cited 1×
“Similarly, while epigenetic silencing of BRCA1 and RAD51C by hypermethylation of promoter regions results in PARPi sensitivity, demethylation is associated with mRNA re-expression and development of resistance [64, 73, 74].”
BackgroundJoshi, P. M., Sutor, S. L., Huntoon, C. J., & Karnitz, L. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551143 · Cited by 199
PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification
Langelier, M.-F., Eisemann, T., Riccio, A. A., & Pascal, J. M. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2018.11.002 · Cited by 196 · cited 2×
“In its non-DNA bound state, PARP1 has minimal catalytic activity due to an auto-inhibitory helical domain (HD) interaction with its catalytic domain [9].”
BackgroundDNA-PKcs-Mediated Transcriptional Regulation Drives Prostate Cancer Progression and Metastasis
Goodwin, J. F., Kothari, V., Drake, J. M., Zhao, S., Dylgjeri, E., Dean, J. L., Schiewer, M. J., McNair, C., Jones, J. K., Aytes, A., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.06.004 · Cited by 180
Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation
Shroff, R. T., Hendifar, A., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S., Lin, K. K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 174 · cited 1×
“Response rates were 1/16 for veliparib [50] and 3/19 for rucaparib [51].”
BackgroundLowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 159 · cited 1×
“Response rates were 1/16 for veliparib [50] and 3/19 for rucaparib [51].”
BackgroundBRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1
Drost, R., Dhillon, K. K., van der Gulden, H. M. L., van der Heijden, I., Brandsma, I., Cruz, C., Chondronasiou, D., Castroviejo‐Bermejo, M., Boon, U., Schut, E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci70196 · Cited by 146 · cited 1×
“Expression of functional hypomorphic variants of BRCA1 has been associated with resistance to PARPi in patient-derived models [63, 71, 72].”
BackgroundSelf-citationAng, J. E., Gourley, C., Powell, C. B., High, H. A., Shapira‐Frommer, R., Castonguay, V., Grève, J. D., Atkinson, T., Yap, T. A., Sandhu, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1262 · Cited by 141 · cited 1×
“At the same time, if resistant clones have restored DNA repair capacities, some cross-resistance with PARPi is expected [21].”
BackgroundSelf-citationTurner, N. C., Telli, M. L., Rugo, H. S., Mailliez, A., Ettl, J., Grischke, E., Mina, L. A., Balmañà, J., Fasching, P. A., Hurvitz, S. A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1891 · Cited by 141 · cited 2×
“Turner NC, Telli ML, Rugo HS et al. A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations (ABRAZO).”
BackgroundMateo, J., Moreno, V., Gupta, A., Kaye, S. B., Dean, E. J., Middleton, M. R., Friedlander, M. L., Gourley, C., Plummer, R., Rustin, G. J. S., et al. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0435-8 · Cited by 129 · cited 1×
“A modified tablet formulation with enhanced bioavailability was later developed; the current olaparib approved dose is 300 mg tablet twice a day [8].”
BackgroundSelf-citationIntegrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Nacson, J., Krais, J. J., Bernhardy, A. J., Clausen, E., Feng, W., Wang, Y., Nicolas, É., Cai, K. Q., Tricarico, R., Hua, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.08.086 · Cited by 104 · cited 1×
“There is also evidence in preclinical models of the co-existence of other mechanisms of resistance involving, for example, BRCA1 restoration with the removal of barriers to DNA end resection via loss of 53BP1 or proteins from the Shieldin complex, among others [75, 76].”
BackgroundSynergistic Loss of Prostate Cancer Cell Viability by Coinhibition of HDAC and PARP
Chao, O. S., & Goodman, O. B. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0173 · Cited by 94 · cited 1×
“combinations with ATR or HDAC inhibitors) [86, 87], take advantage of the relation between angiogenesis, hypoxia and DNA damage [88], or exploit the cross-talk between DDR and hormone receptor-driven pathways, such as ER and AR in breast and prostate cancer, respectively [89–91].”
BackgroundThe FDA and Genomic Tests — Getting Regulation Right
Evans, B. J., Burke, W., & Jarvik, G. P. (2015) · New England Journal of Medicine · doi:10.1056/nejmsr1501194 · Cited by 81 · cited 1×
“Moreover, emergence of new variants also challenges traditional regulatory frameworks, demanding a continuous reassessment of the data in the postapproval setting [55].”
BackgroundWilson, R. H., Evans, T. J., Middleton, M. R., Molife, L. R., Spicer, J. F., Dieras, V. C., Roxburgh, P., Giordano, H., Jaw‐Tsai, S., Goble, S. M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.36 · Cited by 78 · cited 1×
“Lastly, rucaparib (Clovis Oncology) was initially developed for IV administration but later evolved into an orally available drug, with a recommended dose of 600 mg twice daily [29, 30].”
BackgroundPoly(ADP-ribose) Polymerase 1 Is a Key Regulator of Estrogen Receptor α-dependent Gene Transcription
Zhang, F., Wang, Y., Wang, L., Luo, X., Huang, K., Cy, W., Du, M., Liu, F., Luo, T., Huang, K., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.429134 · Cited by 68
Abida, W. M., Bryce, A. H., Vogelzang, N. J., Amato, R. J., Percent, I. J., Shapiro, J., McDermott, R., Hussain, A., Patnaik, A., Petrylak, D. P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy284.002 · Cited by 54 · cited 1×
“Similar data have been reported in a preliminary analysis of a phase II trial of rucaparib [47].”
ResultBalmañà, J., Domchek, S. M., Tutt, A. N. J., & Garber, J. E. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-11-0048 · Cited by 49 · cited 1×
“Despite these initial encouraging results, several stumbling blocks delayed the clinical development in breast cancer [35].”
ResultSelf-citationSundar, R., Miranda, S., Rodrigues, D. N., Chénard-Poirier, M., Dolling, D. I., Clarke, M., Figueiredo, I., Bertan, C. M., Yuan, W., Ferreira, A., et al. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.011 · Cited by 41
Self-citationNeoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+).
Litton, J. K., Scoggins, M. E., Hess, K. R., Adrada, B. E., Barcenas, C. H., Murthy, R. K., Damodaran, S., DeSnyder, S. M., Brewster, A. M., Thompson, A. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.508 · Cited by 35
DNA repair deficiency sensitizes lung cancer cells to NAD+ biosynthesis blockade
Touat, M., Sourisseau, T., Dorvault, N., Chabanon, R. M., Garrido, M., Morel, D., Krastev, D. B., Bigot, L., Adam, J., Frankum, J. R., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci90277 · Cited by 32
Self-citationMoore, K. N., Secord, A. A., Geller, M. A., Miller, D. S., Cloven, N. G., Fleming, G. F., Hendrickson, A. E. W., Azodi, M., DiSilvestro, P., Oza, A. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.5514 · Cited by 29 · cited 1×
“The development of niraparib in ovarian cancer has focussed on the postplatinum maintenance setting, although preliminary results of a phase II trial evaluating the drug in late-stage disease have been reported [27].”
BackgroundNacson, J., Krais, J. J., Bernhardy, A. J., Clausen, E., Feng, W., Wang, Y., Nicolas, É., Cai, K. Q., Tricarico, R., Hua, X., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.10.009 · Cited by 26
Agarwal, N., Sokol, E. S., Lara, P. N., Ross, J. S., Miller, V., Welsh, A., Gregg, J. P., Frampton, G. M., Ali, S. M., & Chung, J. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy269.049 · Cited by 3 · cited 1×
“A recent study analysed the prevalence of BRCA1/2 alterations across tumour types beyond ovarian and breast cancer, in prostate, skin (non-melanoma), endometrial, pancreatic, and biliary duct cancers the prevalence was 5% [42].”
Background
Cited by
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,696
DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer
Huang, R.-X., & Zhou, P.-K. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,198
Ganesh, K., & Massagué, J. (2021) · Nature Medicine · doi:10.1038/s41591-020-01195-4 · Cited by 1,051
PARP and PARG inhibitors in cancer treatment
Slade, D. (2020) · Genes & Development · doi:10.1101/gad.334516.119 · Cited by 667
“since 2009 have demonstrated PARP inhibitor efficacy in BRCA mutated ovarian and breast cancer, but also prostate, pancreatic cancer, and small cell lung carcinoma (SCLC), irrespective of the BRCA status (Weaver and Yang 2013; Sonnenblick et al. 2015; Mirza et al. 2018; Franzese et al. 2019; Keung et al. 2019; Mateo e…”
InfluentialTargeting mutant p53 for cancer therapy: direct and indirect strategies
Hu, J., Cao, J., Topatana, W., Juengpanich, S., Li, S., Zhang, B., Shen, J., Cai, L., Cai, X., & Chen, M. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01169-0 · Cited by 483
Metadata
- Authors
- Mateo, J., Lord, C. J., Serra, V., Tutt, A., Balmaña, J., Castroviejo-Bermejo, M., Cruz, C., Oaknin, A., Kaye, S. B., & de Bono, J. S.
- Affiliations
- Vall d'Hebron Hospital Universitari (ES)
- Institute of Cancer Research (GB)
- Vall d'Hebron Institute of Oncology (ES)
- Royal Marsden NHS Foundation Trust (GB)
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2019-09
- Volume
- 30
- Issue
- 9
- Pages
- 1437-1447
- ISSN
- 0923-7534 (ISSN-L)
- PMC
- PMC6771225
- OpenAlex
- W2951058429
- Cited by
- 743
- References
- 100
- Citations by year
- 2026: 58 · 2025: 123 · 2024: 81 · 2023: 123 · 2022: 145 · 2021: 128 · 2020: 77 · 2019: 8
- FWCI
- 8.58
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by-nc/4.0/ (vor, 206 d)
- Locations
- Annals of Oncology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Funders
- Prostate Cancer Foundation
- Instituto de Salud Carlos III
- FERO Foundation
- Asociación Española Contra el Cáncer
- AECC-JP Barcelona
- Cancer Research UK
- Department of Health (C12540/A25128)
- NHS funding
- NIHR Biomedical Research Centre
- Institute of Cancer Research
- National Institute for Health Research
- NIHR
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Keywords
- PARP inhibitors, olaparib, talazoparib, niraparib, rucaparib, synthetic lethality, DNA repair deficiency, genomic instability, breast cancer, ovarian cancer, maintenance therapy, platinum-based chemotherapy, PARP inhibitor resistance, predictive biomarkers, homologous recombination defects, precision medicine, prostate cancer, pancreatic cancer, combination therapy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Breast Neoplasms, Female, Humans, Indazoles, Indoles, Ovarian Neoplasms, Phthalazines, Piperazines, Piperidines, BRCA1 Protein, BRCA2 Protein, Genomic Instability
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.